DAWN
Day One Biopharmaceuticals, Inc.
Latest Form 4:Sale$67KbyMerendino Lauren (Chief Commercial Officer) · filed Feb 18, 2026
Day One Biopharmaceuticals, Inc. (DAWN) has 18 SEC Form 4 filings (62 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Apr 23, 2026.
Insiders have net sold $673K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Jeremy Bender
- Employees:181
- HQ:Brisbane, CA, US
- IPO:2021-05-27
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$673K
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
Merendino LaurenFirst in 3 months | Chief Commercial Officer | Sale | 5,814 | $67K | Feb 18 | SEC ↗ |
Bender JeremyFirst in 3 months | CHIEF EXECUTIVE OFFICER | Sale | 15,459 | $179K | Feb 18 | SEC ↗ |
York Charles N IIFirst in 3 months | COO and CFO | Sale | 6,065 | $70K | Feb 18 | SEC ↗ |
Dubow AdamFirst in 3 months | Gen Counsel & Secretary | Sale | 6,395 | $74K | Feb 18 | SEC ↗ |
VASCONCELLES MICHAELFirst filing | Head of Research and Dev. | Sale | 2,728 | $32K | Feb 18 | SEC ↗ |
Dubow AdamFirst filing | Gen Counsel & Secretary | Sale | 4,319 | $39K | Nov 18 | SEC ↗ |
York Charles N IIFirst filing | COO and CFO | Sale | 4,062 | $36K | Nov 18 | SEC ↗ |
Bender JeremyFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 15,894 | $142K | Nov 18 | SEC ↗ |
Merendino LaurenFirst filing | Chief Commercial Officer | Sale | 3,726 | $33K | Nov 18 | SEC ↗ |
Related companies
Day One Biopharmaceuticals, Inc. is in the Healthcare sector.